The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Long-Term Outcome of RPE Allografts in Non-Immunosuppressed Patients with AMD
Abstract
Purpose: To determine the long-term outcome of human retinal pigment epithelium (RPE) transplants in patients with advanced age-related macular degeneration (AMD). Methods: Using pars plana microsurgical techniques, RPE allografts were transplanted subretinally to four groups of AMD patients: five patients received organized patch transplants after removal of choroidal neovascular membranes, four got small patch transplants in dry AMD; suspensions of RPE cells were transplanted in five cases with dry AMD, and two patients with RPE tears. None received immunosuppression. Transplants were followed for 24–38 months by biomicroscopy, fundus photography, SLO microperimetry, and fluorescein angiography. Rejection was defined as loss of visual function over the transplant, development of an exudative response (subretinal fluid with or without neovascularization), fluorescein leakage, and disruption, depigmentation, or encapsulation of the transplant. Results: Four of 16 transplants (25%) presented no clinical signs of rejection. Three of the four small patch transplants remained pigmented and essentially unchanged after 30–32 months. Clinical signs of graft rejection appeared within three months in all cases of neovascular AMD (disrupted blood-retinal barrier, BRB), but after 6 - 20 months in five of nine eyes with non-exudative AMD (intact BRB). Conclusions: Subretinal human RPE allografts present a high rejection rate (75%) without immunosuppression. However, small extrafoveal transplants remained unchanged in shape, size and color for more than two years in non-exudative AMD. A disrupted BRB is likely to enhance graft rejection, which occurs earlier in exudative than in non-exudative AMD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“clinical trials conducted using allogenic RPE cells for the treatment of AMD, 2 decades ago, were all met with graft rejection (38–42).”
From Subretinal therapy: technological solutions to surgical and immunological challenges (2022) · cites this paper as [40]
In the citing paper
“Previous allogeneic RPE cell transplantations in dry AMD resulted in graft rejections in some cases, although it started later in the treatment course and was seen less frequently than in patients with wet AMD (Algvere et al., 1997, Algvere et al., 1999).”
From Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: Preliminary results in Asian patients (2015) · cites this paper as Algvere et al., 1999
Citations
Cites
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 1,990
A role for CD95 ligand in preventing graft rejection
Bellgrau, D., Gold, D. P., Selawry, H. P., Moore, J. K., Franzusoff, A., & Duke, R. C. (1995) · Nature · doi:10.1038/377630a0 · Cited by 1,147
Algvere, P. V., Berglin, L., Gouras, P., & Sheng, Y. (1994) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/bf00184273 · Cited by 346
Self-citationThe Collaborative Corneal Transplantation Studies (CCTS)
(1992) · Archives of Ophthalmology · doi:10.1001/archopht.1992.01080220054021 · Cited by 333
Algvere, P. V., Berglin, L., Gouras, P., Sheng, Y., & Kopp, E. D. (1997) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/bf00941722 · Cited by 264
Self-citationWilbanks, G. A., Mammolenti, M., & Streilein, J. W. (1992) · European Journal of Immunology · doi:10.1002/eji.1830220125 · Cited by 249
Loss and restoration of immune privilege in eyes with corneal neovascularization.
Dana, M. R., & Streilein, J. W. (1996) · PubMed · Cited by 206
Differential expression of the complement regulatory proteins in the human eye.
Bora, N. S., Gobleman, C. L., Atkinson, J. P., Pepose, J. S., & Kaplan, H. J. (1993) · PubMed · Cited by 186
Wilbanks, G. A., & Streilein, J. W. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.8.2610 · Cited by 177
Wilbanks, G. A., Mammolenti, M., & Streilein, J. W. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.9.3018 · Cited by 143
Research works printed but not linked: 13
- Yamamoto S., 1993, Invest Ophthalmol Vis Sci, 34, 3068
- Zhang X., 1998, Invest Ophthalmol Vis Sci, 39, 1021
- Sheng Y., 1995, Invest Ophthalmol Vis Sci, 36, 381
- Dana M.R., 1996, Invest Ophthalmol Vis Sci, 37, 2485
- Crafoord S., 1998, Invest Ophthalmol Vis Sci, 39, S98
- Rezai K.A., 1997, Invest Ophthalmol Vis Sci, 38, 2662
- Dafgård Kopp E.M.E., 1997, Invest Ophthalmol Vis Sci, 38, S947
- Liversidge J.M., 1988, Clin Exp Immunol, 73, 489
- Medawar P., 1948, Br J Exp Pathol, 29, 58
- Bora N.S., 1993, Invest Ophthalmol Vis Sci, 34, 3579
- Knisely T.L., 1991, Invest Ophthalmol Vis Sci, 32, 2423
- Grisanti S., 1997, Invest Ophthalmol Vis Sci, 38, 1619
- Hoffman L.M., 1997, Invest Ophthalmol Vis Sci, 38, 2224
Cited by
Sorted by citations
Items 201–217 of 217
Cell-Based Therapies to Restrict the Progress of Photoreceptor Degeneration
Lund, R. D., & Wang, S. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-186-4_17
de Juan, E., & Fujii, G. Y. (2006) · Elsevier eBooks · doi:10.1016/b978-0-323-02598-0.50157-9
Immunochemical analysis of the integrin expression in retinal pigment epithelial cellsPreprint
Heller, J. P., Heintz, T. G., Kwok, J. C. F., Martin, K. R. G., & Fawcett, J. W. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.26.133553
Treumer, F., Klatt, C., & Roider, J. (2007) · Der Ophthalmologe
Karamichos, D. (2016) · MDPI eBooks · doi:10.3390/books978-3-03842-202-0
Tissue Engineering Therapies for Ocular Regeneration
(2016) · CRC Press eBooks · doi:10.1201/9781315368955-9
Kimbrel, E. A., & Lanza, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00064-2
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.8.1246
New Experimental Therapeutic Approaches for Degenerative Diseases of the Retina
Tombran‐Tink, J. (2003) · CRC Press eBooks · doi:10.1201/9780203912072.ch18
Dagnelie, G., Weiland, J. D., Sadda, S. R., & Eong, K. A. (2002) · Elsevier eBooks · doi:10.1016/b978-012436636-7/50215-9
Update on stem/progenitor cell-based clinical trials for eye disease
El-Hashash, A. H. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99987-8.00003-5
Mano, F., LoBue, S., Tailor, P. D., & Olsen, T. W. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.08.002
Cell therapy limits loss of vision in an animal model of retinal degenerative disease
McGill, T. J. (2004) · Open ULeth Scholarship (OPUS) (University of Lethbridge)
Stem Cell-Based Therapeutics in Ophthalmology: Application Toward the Design of Clinical Trials
Gelman, R., & Tsang, S. H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5493-9_11
The aging eye: navigating molecular mechanisms and innovative interventions
Lin, Y., Han, Z., Zhang, Y., Yuan, R., Huang, M., Liu, Y., Wang, J., Xu, C., Liu, L., Yu, P., et al. (2026) · Biogerontology · doi:10.1007/s10522-026-10443-y
Retrospective analysis of subretinal surgery
Falkner, C. I., Binder, S., & Leitich, H. (2004) · Springer eBooks · doi:10.1007/978-3-7091-7985-7_11
Metadata
- Authors
- Algvere, P. V., Gouras, P., & Dafgård Kopp, E.
- Affiliations
- Linköping University (SE)
- Columbia University (US)
- Department of Ophthalmology, Karolinska Institute, St. Erik's Eye Hospital, Stockholm - Sweden
- ORCID
- Gouras, P.
- Venue
- European Journal of Ophthalmology
- Publisher
- SAGE Publications
- Published
- 1999-07
- Volume
- 9
- Issue
- 3
- Pages
- 217-230
- ISSN
- 1120-6721 (ISSN-L)
- 1724-6016
- OpenAlex
- W1480779622
- Cited by
- 219
- References
- 31
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 4 · 2023: 8 · 2022: 3 · 2021: 8 · 2020: 9 · 2019: 9 · 2018: 9 · 2017: 6 · 2016: 6 · 2015: 13 · 2014: 4 · 2013: 4 · 2012: 11
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- age-related macular degeneration, graft rejection, non-immunocompromised patient, subretinal transplantation, choroidal neovascularization, dry age-related macular degeneration, long-term outcomes
- MeSH terms
- Age Factors, Aged, Female, Fluorescein Angiography, Graft Rejection, Humans, Immunosuppression Therapy, Macular Degeneration, Male, Middle Aged, Pigment Epithelium of Eye, Pregnancy, Ophthalmologic Surgical Procedures, Time Factors, Transplantation, Homologous, Vitrectomy, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
